NDC product
BioThrax
NDC 64678-211 · Emergent BioDefense Operations Lansing, LLC
Key facts
| Product NDC | 64678-211 |
|---|---|
| Proprietary name | BioThrax |
| Nonproprietary name | Anthrax Vaccine Adsorbed |
| Substances | BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR, SUBCUTANEOUS |
| Labeler | Emergent BioDefense Operations Lansing, LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA103821 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Anthrax Vaccines [Chemical/Ingredient], Live Attenuated Bacillus Anthracis Vaccine [EPC], Vaccines, Attenuated [Chemical/Ingredient] |
| Marketing start | Nov 4, 1970 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: